Protamine Sulphate
Brand names: Protamine Sulphate Injection
Protamine sulphate is an intravenous antidote used to neutralise the anticoagulant effect of heparin, principally unfractionated heparin, for example after cardiopulmonary bypass or in heparin-related bleeding.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a strongly basic protein it binds the acidic heparin molecule to form an inactive, stable salt, abolishing heparin's potentiation of antithrombin; it only partially reverses low-molecular-weight heparins.
Prescribing in practice
- Rapid injection can cause severe hypotension, bradycardia and anaphylactoid reactions, so it must be given slowly with the dose titrated to the heparin to be neutralised.
- An excess of protamine itself has an anticoagulant effect, so avoid overdosing.
- Patients exposed to protamine-containing insulins, those with fish allergy, and vasectomised or infertile men may be at higher risk of hypersensitivity.
Monitoring
Monitor blood pressure, heart rate and the activated clotting time or APTT during and after administration to confirm heparin neutralisation.
Counselling the patient
- Inform the team this is given slowly to avoid a sudden fall in blood pressure.
- Reversal of low-molecular-weight heparin is only partial and bleeding may recur.
- Report any flushing, breathlessness or feeling faint during administration.
Evidence & guidelines
Protamine is the established antidote for unfractionated heparin and provides partial reversal of low-molecular-weight heparins.
Reference: BCSH guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO